NeuroPace (NPCE) Cash & Equivalents (2020 - 2026)

NeuroPace's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 45.3% year-over-year to $14.8 million in Q1 2026; TTM through Mar 2026 was $14.8 million, a 45.3% decrease from a year earlier, with the FY2025 full-year figure at $21.7 million, up 61.52% from the prior year.
• Cash & Equivalents slipped to $14.8 million in Q1 2026 per NPCE's latest filing, from $21.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $27.0 million in Q1 2025 and bottomed at $5.7 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $13.0 million (2024), against an average of $13.5 million.
• Across the five-year window, Cash & Equivalents tumbled 81.75% in 2022 and jumped 173.4% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $6.6 million in 2022, then soared by 173.4% to $18.1 million in 2023, then retreated by 25.63% to $13.4 million in 2024, then soared by 61.52% to $21.7 million in 2025, then plunged by 31.87% to $14.8 million in 2026.
• Per Business Quant, the three latest NPCE Cash & Equivalents figures stand at $14.8 million (Q1 2026), $21.7 million (Q4 2025), and $20.6 million (Q3 2025).